Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pertschuk, L. P.
Right arrow Articles by Greene, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pertschuk, L. P.
Right arrow Articles by Greene, G. L.

Annals of Surgical Oncology, Vol 1, Issue 6 495-503, Copyright © 1994 by Society of Surgical Oncology

ARTICLES

Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up

L. P. Pertschuk, R. J. Macchia, J. G. Feldman, K. A. Brady, M. Levine, D. S. Kim, K. B. Eisenberg, E. Rainford, G. S. Prins and G. L. Greene
Department of Pathology, State University of New York, Brooklyn.

BACKGROUND: Numerous problems are associated with biochemical androgen receptor (AR) assay performance and interpretation in prostatic cancer. The purpose of this study was to determine if a novel immunocytochemical AR assay performed on intact tissue sections would prove useful in prognosticating endocrine response and survival. METHODS: A prospective study was done on 63 prostatic carcinomas maintained in liquid nitrogen for over a decade. The study used the peroxidase-antiperoxidase system and a polyclonal anti-AR antibody. RESULTS: Marked tissue and cellular heterogeneity of nuclear AR was apparent. A cut-off of 10% AR-positive cells maximized assay prognostic efficiency. Frequency of positivity was 48% and correlated significantly with endocrine response (p = 0.03), time to progression (p = 0.0016), and survival (p = 0.02), but not with grade, stage, or ethnicity. CONCLUSIONS: This AR assay could be prognostically useful in the clinical management of prostate cancer and is suitable for use in the community hospital laboratory.


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
E. L. Bittman, D. A. Ehrlich, J. L. Ogdahl, and A. E. Jetton
Photoperiod and Testosterone Regulate Androgen Receptor Immunostaining in the Siberian Hamster Brain
Biol Reprod, September 1, 2003; 69(3): 876 - 884.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Society of Surgical Oncology.